AB Science Reports a Cash Position of €10.2 Million at the End of 2025 and Continues Its Clinical Refocus
AB Science announced its annual results for 2025, showing a non-recurring operating deficit reduced to €3.8 million, a 38% decrease from 2024. Including the cancellation of a repayable advance accounted as a deduction from research and development expenses, the operating result turned positive at €639,000. The net loss was reduced to €1.6 million, down from €7.8 million a year earlier. The company had €10.2 million in cash as of December 31, 2025, with an additional €3.2 million raised through a private placement in April 2026. AB Science is focusing its resources on Phase III of masitinib in amyotrophic lateral sclerosis and Phase I of AB8939 in acute myeloid leukemia.
Significant Reduction in Expenses in 2025
AB Science's operating income in 2025 solely consisted of revenue from the commercialization of a veterinary medicine, which amounted to €1.174 million, up 10% from €1.072 million in 2024. Operational expenses decreased by 93%, or €6.620 million, between 2024 and 2025. This change was primarily due to the cancellation of a repayable advance of €4.432 million, accounted as a reduction in research and development expenses, a 31% decrease in administrative expenses amounting to €948,000, and a 40% reduction in non-recurring R&D expenses totaling €1.594 million.
Positive Operating Result After Non-Recurring Item
The operating result for 2025 was positive at €639,000, compared to an operating loss of €6.083 million in 2024. Excluding non-recurring events, the operating deficit was €3.793 million, down 38% from €6.083 million the previous year. The financial result was a loss of €2.196 million in 2025, compared to a loss of €1.749 million in 2024. Overall, the annual net loss amounted to €1.557 million, an 80% reduction from €7.831 million in 2024.
Focus on ALS and AB8939
In amyotrophic lateral sclerosis, AB Science states that the confirmatory Phase III study AB23005 with masitinib has been authorized by the first set of European countries—Spain, Greece, and Slovenia—under the CTIS, following validation by the EMA of the harmonized protocol and authorization from the FDA. The study is set to include 408 patients and aims to confirm the efficacy and tolerability of masitinib at a dose of 4.5 mg/kg/day in combination with riluzole, after 48 weeks of treatment. AB Science recalls that previous results from AB10015 in the targeted population showed a median overall survival increase of 12 months.
